Most Searched
We offer corneal cross-linking (CXL), an innovative treatment for keratoconus.
Telehealth appointments are available.
Over time, the cornea (the clear, dome-shaped front surface of the eye) can begin to thin and weaken. When this happens, the cornea loses its dome shape and bulges into a cone shape, distorting your vision and making it hard to see. When this occurs, it’s called keratoconus. The cause is unknown, but research shows that family history, age and disorders such as Down syndrome may lead to the condition. Our surgeons perform a corneal transplant in severe cases of keratoconus.
Corneal cross-linking (CXL) is a newer FDA-approved treatment for keratoconus. It is the only treatment to prevent keratoconus from getting worse. The treatment uses a combination of ultraviolet A light irradiation and the application of riboflavin (vitamin B2) eye drops to stabilize your cornea.
Our USC Roski Eye Institute clinicians have been at the forefront of advancing corneal cross-linking treatment for keratoconus.
Our doctors were among the earliest investigators in Europe to study corneal cross-linking and treat patients with progressive keratoconus and post-LASIK ectasia.
We have been one of the nation’s top ophthalmology programs for over 28 years.
We develop a treatment plan personalized to you and your needs.
Our clinicians participate in the National Institutes of Health–sponsored clinical trial studies of the most state-of-the-art corneal treatments.
LOS ANGELES — Keck Hospital of USC earned an “A” Hospital Safety Grade from...
